-
Posted by
Two Blokes 5 hours ago -
Filed in
Stock
-
0 views
We initiate coverage on Cidara Therapeutics with a Strong Buy rating due to its strategic pivot to antiviral CD388 and promising Phase 2b trial data. Rezafungin's successful approval and divestiture to Mundipharma validate Cidara's development capabilities and free resources for advancing CD388. CD388 shows potential for season-long influenza protection, with promising Phase 2a data and a well-funded Phase 2b trial targeting high-risk patients.
